Login to Your Account



EpiTherapeutics, Abbott in Epigenetics Oncology Deal

By Cormac Sheridan


Wednesday, December 22, 2010
EpiTherapeutics ApS, which is developing cancer drugs based on epigenetics targets, entered its first drug discovery pact, with Abbott, of Abbott Park, Ill. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription